Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecotabart Vedotin + Tislelizumab in First-Line CLDN18.2+ Gastric/GEJ Adenocarcinoma
NCT07385703Phase 3Recruiting
- Sponsor
- Chia Tai Tianqing
- Start
- Apr 2026
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tpx-4589 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Chia Tai Tianqing. Started Apr 2026; status: recruiting.
02
Drugs
tpx-4589
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07385703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07385703.